Atai Life Sciences Archives

Atai posts $26M loss, but progresses on psychedelic clinical trials

New York-based Atai Life Sciences (Nasdaq: ATAI) reported a net loss of $26.3 million for the third quarter, down year-over-year from its net income of $43.3...

Atai Life Sciences1 year ago

Atai’s cash levels fall as company assures investors it has enough money

Atai Life Sciences (NASDAQ: ATAI) announced its second-quarter 2024 financial results and provided corporate updates. The company has little revenue to report as it is in...

Atai Life Sciences1 year ago

Atai bids to buy IntelGenx

Atai’s proposal to purchase the company will serve as a stalking horse bid under the Sale and Investment Solicitation Process. IntelGenx Corp. (OTCQB: IGXT) (TSX: IGX)...

MScannaBIZ.com

Atai extends cash runway into 2027 despite $39M fourth-quarter loss

Atai Life Sciences

Atai Life Sciences prices $55 million offering

Atai, Awakn make progress on treatments for alcohol use disorder

Atai posts $26M loss, but progresses on psychedelic clinical trials

Atai’s cash levels fall as company assures investors it has enough money

Atai bids to buy IntelGenx

Millennials Are Spending Big on Luxury Travel

Ohio Lawmakers Advance Bill To Scale Back Voter-Approved Marijuana Law And Impose Hemp Regulations

Data Confirms Cannabis Is Safer Than Alcohol

Alert: Department of Cannabis Control updates data dashboards with full data for 2023

Connecticut Appoints The US’s First Cannabis Ombudsperson – Yes there is a pun in there and I’m Sure Erin Kirk Is Going To Hear It More Than Once!

5 best CBD creams of 2024 by Leafly